Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions

This activity was originally broadcast in conjunction with the 2023 Asembia Specialty Pharmacy Summit.

Program Description

Lung cancer is the most commonly diagnosed cancer and a leading cause of cancer deaths in the United States. Non−small cell lung cancer (NSCLC) associated with exon 20 insertion mutations occurs in approximately 10% of epidermal growth factor receptor (EGFR) mutations and is often resistant to conventional EGFR tyrosine kinase inhibitors. Until recently, there were no targeted therapies available specifically for patients with exon 20 insertion mutations. This program will review data supporting the use of targeted therapies as well as their place in treatment for patients with exon 20 EGFR-positive NSCLC. Included patient case discussions will detail opportunities for oncology pharmacists to incorporate biomarker testing into treatment plans for patients with NSCLC as well as manage drug interactions and adverse effects. Additionally, the scope of the pharmacist’s role on the multidisciplinary oncology team in alleviating barriers to accessing specialty medications for exon 20 EGFR-positive NSCLC and improving utilization of these agents will be reviewed.

Target audience: Specialty, oncology, and managed care pharmacists

Type of activity: Application
Release date: May 19, 2023
Expiration date: May 19, 2024

Time to complete activity: 1.5 hours

Learner level: Foundational, intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Customize patient counseling on the similarities and differences of epidermal growth factor receptor (EGFR) exon 20-targeted therapies in non–small cell lung cancer (NSCLC) to increase their involvement in treatment decisions
• Apply patient- and disease-specific factors to treatment selection after frontline chemotherapy failure in patients with EGFR exon 20 insertion-positive NSCLC
• Identify opportunities within specialty pharmacy practice to aid in the mitigation, recognition, and management of adverse effects of EGFR exon 20-targeted therapies
• Employ successful strategies for overcoming barriers to treatment access in specialty pharmacy practice

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-237-H01-P. The activity is available for CE credit through May 19, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Chelsey Lindner, PharmD, BCOP, CSP; and Bryan Fitzgerald, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms